Class / Patent application number | Description | Number of patent applications / Date published |
514572000 | Cyclic carboxylic acid containing three to five carbons or cyclic percarboxylic acid containing three to five carbons or salt thereof | 39 |
20090082453 | Exogenous Methyl Dihydrojasmonate for Prevention and Control of Biotic Attack in Plants - Formulations and methods for treating and preventing biotic attack, including disease and insect infestation, in plants are disclosed. The formulations include methyl dihydrojasmonate: | 03-26-2009 |
20130331454 | PKC-EPSILON ACTIVATOR - The present invention aims to obtain an optical isomer of DCP-LA, which shows more superior activity and is suitable for clinical utilization, and provide an agent having a superior PKC-ε activation action, a prophylactic and/or therapeutic agent for neurotransmitter release disorders, and a prophylactic and/or therapeutic agent for neuropsychiatric diseases, which contain the isomer as an active ingredient. | 12-12-2013 |
20160045415 | ELASTIN SYNTHESIS/REGENERATION PROMOTING AGENT - 8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) has an action to promote synthesis and regeneration of elastin, and is useful as an agent for the prophylaxis or improvement of wrinkles, and an anti-aging drug. | 02-18-2016 |
20160089352 | CELL MEMBRANE TRANSPORT PROMOTER FOR SELECTIVE 5-HT1A SEROTONIN RECEPTORS - Provided is a cellular membrane trafficking promoter for a 5-HT | 03-31-2016 |
514573000 | Cyclopentyl or cyclopentene (e.g., prostaglandins, etc.) | 35 |
20080200550 | Inhibition of Hiv-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein - Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing. | 08-21-2008 |
20080207759 | METHOD FOR PROTECTING MITOCHONDRIA - The present invention relates to a method for protecting mitochondria from damage in a mammalian subject, which comprises administering an effective amount of a prostaglandin compound to a subject in need thereof. Also provided is a method for treating mitochondrial dysfunction as well as a condition associated with mitochondrial dysfunction in a mammalian subject, which comprises administering an effective amount of a prostaglandin compound to a subject in need thereof. | 08-28-2008 |
20080287544 | Method for Screening Substance by Measuring PPAR DELTA Activating Effect and Agent - The present invention provides a method for screening a substance having a thermogenesis enhancing effect containing a compound having an effect activating PPARδ, an agent containing the compound, and an agent having antidiabetic, antiobestic or visceral accumulated fat-lowering function. | 11-20-2008 |
20090054524 | Methods for identifying and using IKK inhibitors - The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2. | 02-26-2009 |
20090118373 | Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops - A natural formulation of compounds isolated or derived from hops which inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX) is disclosed. The hops formulations may be administered to a mammal to treat or inhibit a pathological condition associated with the activity of COX-2 and/or 5-LOX in such a mammal. | 05-07-2009 |
20090197962 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY - Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein. | 08-06-2009 |
20100069497 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES - Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: | 03-18-2010 |
20100087540 | PHARMACEUTICAL COMPOSITION - Provided is a pharmaceutical composition comprising: a) a prostaglandin compound; (b) a sugar alcohol; (c) a polyol; and (d) a pharmaceutically acceptable carrier. The composition of the present invention can be stored stably even in a polyethylene container. In addition, the composition of the present invention can be stored stably for a long term even if it comprises only a small amount of a preserving agent. | 04-08-2010 |
20100179222 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES - Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: | 07-15-2010 |
20100184862 | PROSTACYCLIN DERIVATIVES - This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors. | 07-22-2010 |
20100204331 | PROSTAGLANDIN DERIATIVE-CONTAINING AQUEOUS LIQUID PREPARATION - Provided is an aqueous liquid preparation comprising: (a) any one of a prostaglandin derivative being represented by the following formula (I), a pharmaceutically acceptable salt thereof and a hydrate thereof; and (b) at least one polyol of glycerin, propylene glycol, dipropylene glycol and 1,3-butylene glycol. | 08-12-2010 |
20100204332 | METHOD FOR TREATING A DISEASE OR CONDITION RESPONSIVE TO OPENING OF C1C-2 CHANNEL - Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ to be transplanted can also be treated with the ClC-2 channel opener. | 08-12-2010 |
20100234466 | Compositions and Methods for Reducing Body Fat - The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions. | 09-16-2010 |
20100267832 | METHOD FOR TREATING MACULAR DEGENERATION - Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F | 10-21-2010 |
20100324142 | HYDROCORTISONE DERIVATIVES AND USE THEREOF FOR THERAPEUTIC OR COSMETIC INDICATIONS - The present invention relates to hydrocortisone derivatives, the method of production thereof and the therapeutic or cosmetic use thereof to combat hair loss or in the treatment of cutaneous physiopathologies. | 12-23-2010 |
20120022164 | EXTERNAL PREPARATION COMPRISING PROSTAGLANDIN DERIVATIVE - Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): | 01-26-2012 |
20120088836 | USE OF A JASMONIC ACID COMPOUND FOR TREATING GREASY SKIN - The invention relates to a method for cosmetically treating oily skin, including the topical application onto the skin of a composition containing a jasmonic acid compound in a physiologically acceptable medium. | 04-12-2012 |
20120322876 | COSMETIC COMPOSITION COMPRISING A JASMONIC ACID COMPOUND - The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a jasmonic acid compound and a non-ionic associative polyurethane/polyether polymer. | 12-20-2012 |
20130035393 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 02-07-2013 |
20130190404 | CRYSTALS OF CARBOPROST TROMETHAMINE AND THE PREPARATION METHOD AS WELL AS THE USES THEREOF - Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has characteristic peaks in the X-ray diffraction pattern at the following 2θ angles: 6.6±0.2°, 9.9±0.2°, 18.5±0.2° and 20.1±0.2°. Furthermore, also disclosed are preparation method and the use of the crystal. | 07-25-2013 |
20140031428 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 01-30-2014 |
20140039058 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 02-06-2014 |
20140142188 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM - Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part. | 05-22-2014 |
20140155486 | Administration of Iloprost as Aerosol Bolus - The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology. | 06-05-2014 |
20140206766 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM - Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part. | 07-24-2014 |
20140213654 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM - Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part. | 07-31-2014 |
20140235723 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 08-21-2014 |
20140275266 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND METHODS OF USE FOR SAME - Embodiments described herein are directed to prostanoid (IP) receptor agonist compounds, including cicaprost and certain prodrugs, and methods of preparation and use for the same. Certain embodiments are directed to the use of cicaprost and certain prodrugs in the treatment of topical and ocular conditions. | 09-18-2014 |
20150011638 | ALPROSTADIL AND LIDOCAINE TREATMENT OF PREMATURE EJACULATION - Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C | 01-08-2015 |
20150018423 | Injectable Osteogenic Formula and Method of Using Same - Formulations and methods for growing hone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix. | 01-15-2015 |
20150126609 | PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY -PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND - Provided is a pharmaceutical composition including an 11-deoxy-prostaglandin compound represented by formula (I): | 05-07-2015 |
20150290153 | ADMINISTRATION OF AEROSOLISED ILOPROST - The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology. | 10-15-2015 |
20160081954 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE - In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E | 03-24-2016 |
20160106757 | OPHTHALMIC SOLUTIONS - An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative. | 04-21-2016 |
20190142719 | COSMETIC COMPOSITION COMPRISING A JASMONIC ACID COMPOUND | 05-16-2019 |